Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Alpha-Synuclein

Financiado

Blocking the prion like disease propagation in Parkinson s disease and related d...

Blocking the prion like disease propagation in Parkinson s disease and related disorders model development and identification of cell autonomous and cell non autonomous factors. A prion-like behavior of α-synuclein (AS) protein has been hypothesized in the pathogenesis of Parkinson disease (PD). According to this hypothesis, pathogenic forms seeds of AS propagate from periphery into the neurons of central... ver más

31/08/2021

200K€

Presupuesto del proyecto: 200K€

Líder del proyecto

AARHUS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-08-31

MSCA-IF-2017: Individual Fellowships

I+D

Cerrada hace 7 años

0% 100%

2 Participantes

200.19K€ | Lider

REFRACTARIOS ALFRAN

309.90K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2017-85199-P CCAAT/ENHANCER BINDING PROTEIN BETA (C/EBPBETA) COMO MODULAD... 218K€ Cerrado

SAF2012-34556 PAPEL DE LA PROTEOSTASIS DE ALFA-SINUCLEINA Y DJ-1 EN LA FUN... 117K€ Cerrado

PID2020-120380RB-I00 USO DE VECTORES VIRALES ADENO-ASOCIADOS PARA EL DISEÑO Y VAL... 158K€ Cerrado

PID2019-105136RB-I00 CONEXION ENTRE EL ESTRES DEL RETICULO ENDOPLASMICO Y LA ALFA... 167K€ Cerrado

SAF2012-33816 CARACTERIZACION DE LOS MECANISMOS INTRINSECOS IMPLICADOS EN... 187K€ Cerrado

SAF2017-89402-R RELACION ENTRE LRRK2 Y EL DEFICIT DE TRAFICO VESICULAR MEDIA... 169K€ Cerrado

Duración del proyecto: 42 meses Fecha Inicio: 2018-02-26
Fecha Fin: 2021-08-31

Líder del proyecto

AARHUS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 200K€

Descripción del proyecto A prion-like behavior of α-synuclein (AS) protein has been hypothesized in the pathogenesis of Parkinson disease (PD). According to this hypothesis, pathogenic forms seeds of AS propagate from periphery into the neurons of central nervous system (CNS), where they recruit endogenous AS in the first receiving neurons, exit the cell and enter connected neurons. The ongoing AS aggregation and cell-cell propagation is considered to induce oxidative stress, neuronal dysfunction and neuronal loss in CNS. Therefore, blocking the neuronal propagation of AS will prevent AS neurotoxicity and neurodegeneration. I propose to develop and validate a novel in vivo model of prion-like AS propagation, in which I will selectively modify the genetic makeup of first receiving neurons, and use this model for mechanistic investigations. I will use a transgenic M83 mouse model overexpressing mutant A53T human AS in which prion-like spreading is initiated by injecting preformed AS aggregates into the hindlimb musculus femoris. These AS aggregates are taken up by sensory and/or motor nerve endings in the muscle, are retrogradely transported through the sciatic nerve into spinal cord, and rostrally into the brainstem and higher brain areas over time. I will refine this model by transducing the sciatic nerve endings with intramuscular delivery of rAAV viral vectors- containing novel CRISPR/Cas9 genome editing tools targeting genes of interest- to prevent in vivo prion-like AS spreading and/or toxicity. As proof of concept, I will silence AS in the receiving neurons to demonstrate this slows the disease development in the model. Once validated, I will use the model for hypothesis-driven mechanistic investigations of candidate genes, which initially include: 1) ubiquitin specific peptidase 19 (USP19)- since it has been implicated in cellular excretion of misfolded AS in vitro, and 2) eukaryotic elongation factor-2 kinase (eEF2K)- since it is abnormally activated in postmortem PD brain tissue.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores